Genetic News and Research

RSS

Neogen fourth quarter revenues increase 11.4% to $48,545,000

Neogen Corporation announced today that its revenues for the fourth quarter of its FY 2012, which ended May 31, increased 11.4% from the previous year's comparable quarter to $48,545,000. Net income for the fiscal year's final quarter was $0.25 per share, the same as the prior year's fourth quarter of $0.25 per share.

24 Jul 2012

Topline results from first of four Phase 3 studies of Pfizer's bapineuzumab for Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype.

24 Jul 2012

New FDA guidelines on HIV And TB drug doses may not apply to African and Asian patients

In January, 2012, the U.S. Food and Drug Administration (FDA) issued new guidelines on dosing of an HIV medication used to treat people infected with both HIV and tuberculosis (TB) because of a potential interaction between two of the main drugs used to treat each disease.

24 Jul 2012

Study represents new use of bone marrow transplantation

Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract.

24 Jul 2012

Study reveals 50% increased risk of urothelial and colorectal cancers in adulthood

Parents are increasingly conscious of the dangers of childhood obesity. There is a growing recognition of health problems associated with extra pounds, including the risk of diabetes, heart disease, and joint and muscle pain.

24 Jul 2012

Illumina sues IBS and Qiagen for infringement of three patents

Illumina, Inc. today announced that the company has sought leave to file counterclaims against Intelligent Bio-Systems, Inc. and Qiagen NV, which recently acquired IBS, in response to the patent lawsuit brought by Columbia University and IBS on March 26, 2012 in U.S. District Court in Wilmington, Delaware.

From Illumina, Inc. 23 Jul 2012

Protein associated with Huntington’s and other neurodegenerative diseases has several brain-specific forms

A protein essential for metabolism and recently associated with neurodegenerative diseases also occurs in several brain-specific forms. This discovery emerged in the course of a research project funded by the Austrian Science Fund FWF, the findings of which have now been published in the journal Human Molecular Genetics.

23 Jul 2012

Genetic underpinnings of Wiedemann-Steiner syndrome identified

Researchers have identified a genetic underpinning of Wiedemann-Steiner syndrome.

23 Jul 2012

Egg allergy treatment for children: an interview with Dr Robert Wood

The tendency to get allergies is a fairly general one, which is mostly inherited – it tends to run in families. There are several foods that are most common for children to become allergic to: milk, egg and peanuts in most countries are the most common food allergies.

23 Jul 2012

HIV-positive women may use new methods to help reduce frequency of cervical cancer screening

Compared to the general population, HIV-positive women have a high risk of cervical cancer and thus are advised to undergo more frequent screening tests. This creates a burden for HIV-positive patients and the health care system, leading to frequent biopsies, which often do not reveal clinically relevant disease.

23 Jul 2012

Researchers identify several gene mutations responsible for medulloblastoma

Researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital have identified several gene mutations responsible for the most common childhood brain tumor, called medulloblastoma, adding evidence to the theory that the diagnosis is a group of genetically distinct cancers with different prognoses. These and accompanying findings are likely to lead to less-toxic, better-targeted treatment approaches over the next two years, the researchers said.

23 Jul 2012

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Researchers at Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and several collaborating institutions have linked mutations in specific genes to each of the four recognized subtypes of medulloblastoma, the most common malignant brain tumor of children. The discovery, reported July in the journal Nature, provides doctors with potential biomarkers for guiding and individualizing treatment and reveals prospective therapeutic opportunities for countering this devastating malignancy.

23 Jul 2012

Researchers turn inanimate silicone and living cardiac muscle cells into a jellyfish

Using recent advances in marine biomechanics, materials science, and tissue engineering, a team of researchers at Harvard University and the California Institute of Technology (Caltech) have turned inanimate silicone and living cardiac muscle cells into a freely swimming "jellyfish."

23 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

Many patients may benefit from day 5 embryo biopsy

Over the last several years Carolina Conceptions has been offering embryo biopsy to rule out chromosomal abnormalities and genetic diseases in future pregnancies. One of the downsides of the technique was that biopsies were performed after 3 days of embryo culture, which was later discovered to limit the ability of the embryo to undergo normal development. This actually reduced the chance of pregnancy, often erasing any advantage that was provided by the biopsy procedure.

21 Jul 2012

Study identifies genetic markers that influence protein involved in regulating oestrogen, testosterone levels

A research study led by the Peninsula College of Medicine and Dentistry, University of Exeter, and Boston University School of Medicine, in collaboration with a global consortium, has identified genetic markers that influence a protein involved in regulating oestrogen and testosterone levels in the bloodstream.

21 Jul 2012

2-D models may often give researchers misleading results

Imagine millions of cancer cells organized in thousands of small divots. Hit these cells with drugs and when some cells die, you have a candidate for a cancer drug. But a review published this week in the journal Expert Opinion on Drug Discovery argues that these 2D models in fact offer very little information about a potential drug's effects in the body and may often give researchers misleading results.

21 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

uniQure receives positive recommendation from EMA CHMP for Glybera

uniQure announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion that recommends marketing authorization of Glybera (alipogene tiparvovec) as a treatment for lipoprotein lipase deficiency (LPLD) under exceptional circumstances.

21 Jul 2012

Study identifies genetic markers that influence sex hormone-binding globulin

A research study led by Boston University School of Medicine (BUSM) and the University of Exeter in the United Kingdom, in collaboration with a global consortium, has identified genetic markers that influence a protein involved in regulating estrogen and testosterone levels in the bloodstream.

21 Jul 2012

Genetic News and Research

Neogen fourth quarter revenues increase 11.4% to $48,545,000

Topline results from first of four Phase 3 studies of Pfizer's bapineuzumab for Alzheimer's

New FDA guidelines on HIV And TB drug doses may not apply to African and Asian patients

Study represents new use of bone marrow transplantation

Study reveals 50% increased risk of urothelial and colorectal cancers in adulthood

Illumina sues IBS and Qiagen for infringement of three patents

Protein associated with Huntington’s and other neurodegenerative diseases has several brain-specific forms

Genetic underpinnings of Wiedemann-Steiner syndrome identified

Egg allergy treatment for children: an interview with Dr Robert Wood

HIV-positive women may use new methods to help reduce frequency of cervical cancer screening

Researchers identify several gene mutations responsible for medulloblastoma

Researchers link specific gene mutations with four recognized subtypes of medulloblastoma

Researchers turn inanimate silicone and living cardiac muscle cells into a jellyfish

BioDiem presents positive findings of their eye disease drug at international conference

Many patients may benefit from day 5 embryo biopsy

Study identifies genetic markers that influence protein involved in regulating oestrogen, testosterone levels

2-D models may often give researchers misleading results

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

uniQure receives positive recommendation from EMA CHMP for Glybera

Study identifies genetic markers that influence sex hormone-binding globulin

Sequencing & Genomics: Elevating Science and Healthcare eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News